Trial Profile
A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Bortezomib; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CEPHEUS
- Sponsors Janssen Research & Development; Janssen-Cilag
- 26 Mar 2024 Planned End Date changed from 27 Mar 2026 to 31 Oct 2028.
- 03 Jan 2024 Planned End Date changed from 27 Feb 2026 to 27 Mar 2026.
- 05 Dec 2023 Planned End Date changed from 29 Aug 2025 to 27 Feb 2026.